These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33672671)

  • 21.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of Carbapenem-Hydrolyzing Oxacillinases in Acinetobacter baumannii in Children from Croatia.
    Lukić-Grlić A; Kos M; Žižek M; Luxner J; Grisold A; Zarfel G; Bedenić B
    Chemotherapy; 2019; 64(4):167-172. PubMed ID: 31707391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic and genotypic detection of β-lactamases in Acinetobacter spp. isolates recovered from Lebanese patients over a 1-year period.
    Hajjar Soudeiha M; Dahdouh E; Daoud Z; Sarkis DK
    J Glob Antimicrob Resist; 2018 Mar; 12():107-112. PubMed ID: 28986323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Nelson K; Rubio-Aparicio D; Tsivkovski R; Sun D; Totrov M; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases.
    Bou G; Cerveró G; Domínguez MA; Quereda C; Martínez-Beltrán J
    J Clin Microbiol; 2000 Sep; 38(9):3299-305. PubMed ID: 10970374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance.
    Findlay J; Poirel L; Bouvier M; Nordmann P
    J Glob Antimicrob Resist; 2022 Sep; 30():445-450. PubMed ID: 35618210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.
    Yang Q; Xu Y; Jia P; Zhu Y; Zhang J; Zhang G; Deng J; Hackel M; Bradford PA; Reinhart H
    J Antimicrob Chemother; 2020 Jul; 75(7):1833-1839. PubMed ID: 32306049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of
    Ballesté-Delpierre C; Ramírez Á; Muñoz L; Longshaw C; Roca I; Vila J
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant
    Pasteran F; Cedano J; Baez M; Albornoz E; Rapoport M; Osteria J; Montaña S; Le C; Ra G; Bonomo RA; Tolmasky ME; Adams M; Corso A; Ramirez MS
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34068158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.
    Kiffer CR; Sampaio JL; Sinto S; Oplustil CP; Koga PC; Arruda AC; Turner PJ; Mendes C
    Diagn Microbiol Infect Dis; 2005 Aug; 52(4):317-22. PubMed ID: 15936166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles.
    Aubert G; Guichard D; Vedel G
    J Antimicrob Chemother; 1996 Jan; 37(1):155-60. PubMed ID: 8647758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
    Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and changing minimum inhibitory concentration (MIC) of Acinetobacter species from a tertiary care setup.
    Capoor MR; Nair D; Srivastava L; Gupta B; Aggarwal P
    J Commun Dis; 2005 Jun; 37(2):99-107. PubMed ID: 16749272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
    Ling TK; Ying CM; Lee CC; Liu ZK
    Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
    Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
    Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2019.
    Lee YL; Ko WC; Hsueh PR
    Int J Infect Dis; 2023 Feb; 127():48-55. PubMed ID: 36516915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
    J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.